(Q45740317)

15 December 2017

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance (English)

1 reference

15 December 2017

1 reference

1 reference

Gutfreund KS

1

1 reference

15 December 2017

Williams M

2

1 reference

15 December 2017

George R

3

1 reference

15 December 2017

Bain VG

4

1 reference

15 December 2017

Ma MM

5

1 reference

15 December 2017

Yoshida EM

6

1 reference

15 December 2017

Villeneuve JP

7

1 reference

15 December 2017

Fischer KP

8

1 reference

15 December 2017

Tyrrel DL

9

1 reference

15 December 2017

1 September 2000

1 reference

15 December 2017

Journal of Hepatology

1 reference

15 December 2017

33

1 reference

15 December 2017

3

1 reference

15 December 2017

469-475

1 reference

Natural history and control of perinatally acquired hepatitis B virus infection

15 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Hepatitis B: global importance and need for control

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Global status of hepatitis B immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Therapy of viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Hepatitis B virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980284-6

7 January 2021

10.1016/S0168-8278(00)80284-6

Identifiers

DOI

1 reference

15 December 2017

1 reference